The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime. Curing these diseases would be invaluable.The likelihood of that happening is something one can only dream of today. Yet based on research from Wood’s Ark Invest, the companies pursuing these treatments could see their enterprise value race higher by a 28% compounded annual growth rate. That means by the en ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41536 PRIME MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 84-3097762 (State or other jurisdiction of incorporation or organization) 21 ...

-- Progressing broader portfolio across core areas of focus; expect to initiate IND-enabling activities in first liver and ocular disease programs in 2024 -- -- Advancing hotspot and PASSIGE™ Prime Editors for CF following entry into therapeutic development agreement with Cystic Fibrosis Foundation -- -- Completed upsized $161 million public of ering -- Cambridge, Mass., March 1, 2024 – Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-tim ...

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten upsized public offering of 19,200,001 shares of its common stock at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24 ...

Igor Kutyaev/iStock via Getty Images Prime Medicine (NASDAQ:PRME) is at the forefront of gene editing, advancing the boundaries of genetic therapies with its innovative Prime Editing platform. However, the potential of this technology is more than just a theoretical promise; it stems from strategic pipeline developments and preclinical successes. The bullish trend regarding Prime Medicine is supported by investments in R&D as the $41.0 million third-quarter 2023 expenditure increased from the previous y ...

CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the Company with up to $15 million to support the development of Prime Editors for the treatment of Cystic Fibrosis (CF). CF is an inherited genetic disease, which can be caused by more than 1,700 different mutations in ...

Prime Medicine, Inc. (PRME) closed the last trading session at $9.05, gaining 11% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19.13 indicates an 111.4% upside potential.The average comprises eight short-term price targets ranging from a low of $10 to a high of $26, with a standard deviation of $5.67. While the lowest estimate indicates an increase of 10.5% from the current pri ...

CAMBRIDGE, Mass., Jan. 5, 2024 /PRNewswire/ -- Prime Medicine, Inc. (Nasdaq: PRME) ("Prime Medicine") and Myeloid Therapeutics, Inc. ("Myeloid"), today announced resolution of all of their outstanding disputes, signaling an end to the pending arbitrations and a positive outcome for both parties. "I am happy we have reached an amicable settlement with Myeloid. We believe resolving this dispute is in the best interest of our shareholders and allows each company to pursue its goals of developing differentiated ...

CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company's Chief Financial Officer, effective January 17, 2024. A seasoned financial executive with over twenty years' experience in the biotechnology industry, Dr. Reine will be responsible for the company's financing strategy and investor relation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission file number 001-41536 Prime Medicine, Inc. (Exact name of registrant as specified in its charter) (S ...